Latest Breaking News On - Project orbis - Page 4 : comparemela.com

FDA Grants Priority Review to Merck s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

FDA Grants Priority Review to Merck s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDamini chokshiGursel aktanJohn infantiPeter dannenbaumJulie cunninghamRamez eskanderSociety of gynecologic oncologyStatement of merck co incMerck research laboratoriesMoores cancer centerOncology centerDrug administrationUs national cancer instituteNational institutes of healthDevelopment agreement

Merck (MRK) Granted FDA Priority Review for KEYTRUDA Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Merck (MRK) Granted FDA Priority Review for KEYTRUDA Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesGursel aktanRamez eskanderMoores cancer centerUs national cancer instituteSociety of gynecologic oncologyNational clinical trials networkDevelopment agreementUniversity of california san diegoMerck research laboratoriesDrug administrationNational institutes of healthOncology centerBiologics license applicationPrescription drug user fee actGynecologic oncology

US Approves Tagrisso-Chemo Combo for Advanced Lung Cancer 19 February

US Approves Tagrisso-Chemo Combo for Advanced Lung Cancer 19 February
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomDaiichi sankyoDave fredricksonLaurie ambroseLung ambition allianceDrug administrationDana farber cancer institutePriority reviewNew england journalExecutive vice presidentOncology business unitLung cancerPractical guidelinesProject orbisSouth america

AstraZeneca s Tagrisso plus chemotherapy appoved for lung cancer in the US

AstraZeneca's Tagrisso approved in the US for EGFRm non-small cell lung cancer with chemotherapy. FLAURA2 trial results show significant benefit.

United statesDave fredricksonLaurie ambroseAmerican cancer societyPathology labDrug administrationDana farber cancer instituteNational comprehensive cancer networkLungevity foundationNational comprehensive cancer network incPriority reviewNew england journalExecutive vice presidentOncology business unitLung cancerPractical guidelines

AstraZeneca s Tagrisso approved as an important new treatment option

Patients in the US with epidermal growth factor receptor mutated (EGFRm) advanced lung cancer can now receive an important new treatment option delaying disease progression by nearly nine additional months.

Laurie ambroseDave fredricksonDrug administrationDana farber cancer institutePriority reviewNew england journalProject orbisLung cancerClinical developmentLinical evolutionPis active pharmaceutical ingredientsDelivery formulationsPhase iii ivLung cancerSmall molecule drugs